VERNON HILLS, Ill.--(BUSINESS WIRE)--Applied NeuroSolutions, Inc. (OTC BB:APSN)(www.AppliedNeuroSolutions.com), a biotechnology company focused on the development of products for the early diagnosis and treatment of Alzheimer’s disease (“AD”), today announced it has achieved promising results in its development of a blood-based test related to the diagnosis of patients with Alzheimer’s disease (AD). The results of two studies, which provided data from blinded serum samples, showed the ability of this tau-based test to differentiate between patients with AD and normal controls with a sensitivity greater than 80% and a specificity greater than 70%.
